Genesis Fertility Center Public Company LimitedSET: GFC🇹🇭 TH

Business Operation · 2025

Corporate Information

Company Name

Genesis Fertility Center Public Company Limited

Telephone

0-2108-6413-4

Website

www.genesisfertility.co.th

Email

info@gfc.co.th

Dividend Policy

Dividend Policy

The Company has a dividend payment policy of not less than 40% of the net profit from the separate financial statements after deducting corporate income tax, legal reserve funds, and other reserves (if any). The Company will consider dividend payments by taking into account various factors to primarily maximize benefits for shareholders, and such dividend payments must not significantly affect the Company's normal operations. However, such dividend payments may be subject to change, depending on the Company's operating results, financial position, liquidity, necessity for working capital in operations, investment plans, future business expansion, market conditions, suitability, and other factors related to the Company's operations and management, provided that the Company must have sufficient cash for business operations, and such actions must generate the maximum benefit for shareholders as deemed appropriate by the Board of Directors and/or the Company's shareholders.

The resolution of the Board of Directors approving the dividend payment must be submitted for approval at the shareholders' meeting, unless it is an interim dividend payment, which the Board of Directors has the authority to approve. The Board shall then report this to the shareholders' meeting at the next meeting.

Dividends shall not be paid from any funds other than profits. In cases where the company still has accumulated losses, no dividends shall be paid, unless it is a case of preferred shares where the articles of association specify otherwise. Dividends shall be paid according to the number of shares, equally per share, and the payment of dividends must be approved by the shareholders' meeting.

Historical Dividend Payments

This YearLast Year2 Years AgoMetricDescription
0.050.350.45Net profit per share (Baht : Share)Net profit per share (baht : share)
0.130.250.28Dividend per share (Baht : Share)Dividend per share (baht : share)
000Dividend stock ratio (Number of original shares: dividend shares)Ratio of stock dividend payment (existing share : stock dividend)
000Dividend share value per share (Baht : Share)Value of stock dividend per share (baht : share)
0.130.250.28Total dividend payment value (Baht : Share)Total dividend payment (baht : share)
267.971.462.22Dividend payout ratio to net profit (%)Dividend payout ratio compared to net profit (%)

Major Shareholders

Major Shareholders

No.NameShares% Shares
24,928Assoc.Prof.Pitak Laokirkkiat, MD.56,677,40025.76
24,929DR. PRAMUK VONGTANAKIAT40,500,20018.41
24,930MISS PHASIREE ORAWATTANASRIKUL24,555,00011.16
24,931MISS PORRAWAN TANGTHAM16,520,0007.51
24,932Miss Piyada Wiratpong16,355,5007.43
24,933Dr. RUTCHCHAYUTH JERAPORNPRAPA5,754,4002.62
24,934Metha Construction Co., Ltd.4,079,9001.85
24,935MR. SIWAT ORAWATTANASRIKUL3,800,0001.73
24,936MR. KRITSUPOT ORAWATTANASRIKUL3,100,0001.41
24,937MR. JONGJATE AOJANEPONG1,871,9000.85
24,938MISS MITTIKARN JALA1,745,0000.79
24,939MISS NUCHANART PIYABONGKARN1,720,0000.78
24,940UBS AG SINGAPORE BRANCH1,405,0000.64
24,941MR. THANUPHON ORAWATTANASRIKUL1,400,0000.64
24,942Mr. Vichaphan Hemranchroj1,300,0000.59
24,943MR. CHANNASIRI KIATMALAWONG1,210,2000.55

Remark

The Company has disclosed the list of major shareholder groups and the securities holding report of directors and executives in Attachment 10.

Business Strategies Overview

Chairman's Message

Dear Shareholders,


The year 2025 marks another significant milestone in reinforcing GFC’s achievements and capabilities as a leading provider of assisted reproductive technology in Thailand. Following our transition to a listed company on the Stock Exchange of Thailand, we remain committed to advancing our mission of “building complete families” through advanced medical standards and the highest level of medical ethics, amid a societal context characterized by declining birth rates and a rapidly aging population.

GFC recognizes that our mission extends beyond medical treatment. It also contributes to long-term demographic stability. Over the past year, we have continuously expanded our capabilities, both through the strategic expansion of service branches to improve accessibility, and through investments in cutting-edge laboratory technologies to significantly enhance our success rates.

Strategic Direction for 2025

To achieve sustainable growth, the Board of Directors has focused on the following key priorities:

Integrative Innovation: The integration of Artificial Intelligence (AI) and advanced Preimplantation Genetic Testing (PGT) to enable more precise embryo selection, reduce risks, and increase the likelihood of healthy births.

Expansion & Accessibility: The expansion of our service network into high-potential areas to accommodate increasing demand from both Thai and international patients, particularly in the medical tourism segment.

Sustainability & Governance: A commitment to Environmental, Social, and Governance (ESG) principles, emphasizing transparent operations and the development of high-quality next-generation medical professionals.

GFC remains dedicated to being a “Center of Hope”, delivering not only medical treatment but also compassion, understanding, and warmth akin to that of a family. We take pride in being part of the journey of thousands of couples in fulfilling their dreams, while also enhancing Thailand’s position as a regional hub for infertility treatment services.

Finally, on behalf of the Board of Directors, I would like to express my sincere appreciation to our shareholders, business partners, medical professionals, scientists, and all employees for your unwavering dedication and strong collaboration. Your trust is the key driving force behind GFC’s continued stable and sustainable growth.

Vision

To be a leader in medical assisted reproductive technology in the ASEAN region, characterized by stability, sustainability, and adherence to ethical principles.

Objectives

GFC's primary objective is to be a leader in medical reproductive technology (IVF/ICSI), offering comprehensive services with the highest standards. This is aimed at addressing infertility issues, focusing on delivering successful parenthood to families, adhering to ethical principles, and developing technology to elevate Thailand as an international medical hub.

Goals

To be a leader in comprehensive assisted reproductive technology, to treat infertility and fulfill the dreams of couples to have healthy children, by focusing on increasing success rates (IVF/ICSI) above industry standards, along with expanding branches and customer base both domestically and internationally.

Business Strategies

Policies and Business Overview

Genesis Fertility Center Public Company Limited ("GFC" or "the Company") was established on December 8, 2559, with an initial registered capital of 10.00 million Baht, to provide comprehensive medical services for infertile individuals, utilizing one of Thailand's most modern reproductive technologies and innovations. This was founded by Assoc. Prof. Dr. Pitak Laokirkkiat, a specialist in obstetrics, gynecology, and reproductive technology, with over 2 4 years, and Dr. Pramook Wongthanakiart, an obstetrician-gynecologist, along with leading doctors and specialists in reproductive technology, including Dr. Parawan Tangtham, a fertility specialist, Ms. Piyada Wiratpong, a scientist or medical technologist specializing in fertility, as well as Ms. Pasiri Orawattanasri and Mr. Korapat Atchariyamanikul experienced business professionals in medical fertility, who jointly established a specialized obstetrics-gynecology clinic under the name "Genesis Fertility Center" in the Rama 3 area, with the aim of fulfilling every family's dream. This aspiration drives GFC to design and develop services with understanding, genuine knowledge, and meticulous care at every step, from diagnosing the causes of infertility using various service methods tailored to individuals, to ensure the most accurate results before proceeding with careful, detailed, and attentive treatment at every stage. Furthermore, all GFC personnel are ready to provide consultation based on empathy and care for clients as if they were family members throughout the service period, to maximize the chances of successful conception.

"GFC" opened a branch providing infertility treatment services, GFC Ubon Company Limited "GFC Ubon," managed by
Dr. Thitima Chaisrisawasdisuk, Managing Director and specialist in obstetrics-gynecology and reproductive technology, can accommodate patients comprehensively in Ubon Ratchathani and nearby provinces, which will be a clinic for treatment a new standard infertility treatment center in the lower Northeast, capable of providing treatment to neighboring countries under the same standards as "GFC," which will fulfill the dreams of every family with medical services for infertile individuals, possessing expertise and experience in in-vitro fertilization (ICSI), intrauterine insemination (IUI), as well as egg freezing (OOCYTE FREEZING) services, AMH testing, and chromosome testing.

"GFC," a specialist in reproductive medicine, has opened its GFC Rama 9 International branch for infertility treatment, which is a significant landmark, aiming to elevate comprehensive medical services for infertile individuals. It is also preparing to expand its portfolio of international clients, especially Chinese clients, and plans in-depth studies to target CLMV clients, namely Cambodia, Laos, Myanmar, and Vietnam, as well as clients from India and the Middle East, to further expand its customer base in the future, fulfilling the motto "GFC cares for success" and completing the meaning of "the perfect family."

As of December 31 256 8 The Group's five shareholders are Assoc. Prof. Dr. Pitak Laokirkkiat, Dr. Pramook Wongthanakiart, Ms. Pasiri Orawattanasrikul, Ms. Piyada Wiratpong, and Dr. Parawan Tangtham, holding a percentage of shares in the company equal to 25.76 Percentage 18.76 Percentage 9.11 Percentage 7.43 and percentage 7.50 respectively

GFC Ubon Company Limited “GFC Ubon” by Assoc. Prof. Dr. Pitak Laokirkkiat, a specialist in reproductive medicine, with over 24 Dr. . Pramook Wongthanakiart, Obstetrician-Gynecologist Ms. Piyada Wiratpong, Head of Specialized Fertility Scientists (Embryologist), and Mr. Rojjanin Lueangpipatsorn, a businessman and investor

Currently, the Company has 3 subsidiaries, in which the Company holds 99.99% and 99.99% stakes, respectively: (1) Genosomics Company Limited ("GSM") operates a business providing embryo genetic testing services (Next generation sequencing: NGS). (2) GFC Fertility Group Company Limited ("GFCFG"), a holding company, was established for investments in other businesses with the objective of engaging in other activities that benefit or support the Company's operations. GFCFG currently has no commercial revenue and (3) GFC Ubon Company Limited provides treatment and consultation services for infertile individuals. "GFC" holds 60% of the shares, and Dr. Thitima Chaisrisawasdisuk's group holds 40%. The main business operations of the Company and its subsidiaries ("the Group") can be divided into 5 categories:

  1. Initial examination services before providing advice or treatment

  2. Infertility treatment services using IUI (Intrauterine insemination)

  3. Infertility treatment services using ICSI (Intracytoplasmic Sperm Injection)

  4. Embryo genetic testing services (Next generation sequencing: NGS)

  5. Egg freezing and egg banking services

The Group's business operations related to providing comprehensive medical services for infertile individuals, as mentioned above, require knowledge, expertise, as well as authorization and standard certification from relevant regulatory bodies. It is also necessary to strictly adhere to regulations and various specified conditions under the Department of Health Service Support, Ministry of Public Health, to ensure safety and maintain treatment standards, which will contribute to maximizing the chances of successful conception. This has led to the Group being widely and continuously accepted and trusted by customers in terms of quality, standards, and service success.

The Group operates strictly within the framework of relevant laws and regulations in Thailand to maintain standards in reproductive technology operations, which will be of utmost benefit to customers. Furthermore, the Group is committed to using technology and processes that meet customer expectations to ensure customers receive excellent quality services. In 2560, the Group received standard certification for medical reproductive technology services under the Protection of Children Born from Medical Reproductive Technology Act B.E. 2558 (2015) by the Department of Health Service Support, Ministry of Public Health. In 2563, the Group began implementing Early Embryo Viability Assessment (EEVA) technology, an artificial intelligence system ("AI system"), to assist in embryo quality assessment, being the first in Thailand to do so.

Organizational Values (Core Values)

  • Patient-centered: Customer feelings and satisfaction are our core priority.

  • Professional: Professional and expert in all aspects.

  • Prestige customer-service: Providing heartfelt service, treating every customer as a VIP.

  • Pleasure: Happy to serve customers and rejoice in every successful pregnancy.

  • Personnel well-being: Everyone in the team is happy at work.

Competitive Advantages and Business Strategies

Comprehensive Medical Services for Infertile Individuals (One-stop Medical Services) The Group provides comprehensive medical services for infertile individuals, from diagnosing the causes of infertility using various methods, including medical history taking by doctors and blood tests, to deeply and specifically understand each couple's problems, as well as selecting appropriate and cost-effective treatment methods. This is achieved through a combination of modern medicine, science, and technology, such as IUI infertility treatment services, ICSI infertility treatment services, embryo genetic testing (NGS), sperm and embryo freezing, direct testicular sperm extraction, and endometrial receptivity testing before embryo transfer, etc., to maximize the chances of successful conception for patients. Additionally, the Group offers other services related to infertility treatment and future family planning, such as egg freezing and egg banking. Therefore, the Group can provide comprehensive infertility treatment services to patients in one place. The Group thus has an advantage over other competitors in the market and demonstrates itself as one of the leaders in comprehensive infertility treatment with modern reproductive technology in Thailand. For the year ended December 31 256 7 until December 31 256 8 The Group has patient medical records for those who received services from the Group equal to B 1,036 people and 712 people according to Order

Furthermore, the Group also provides patient care up to the pregnancy stage and refers patients to leading hospitals to help complete the creation of a perfect family.

1. Modern Reproductive Technology

The Group focuses on using modern treatment technology with international standards that are practical. Additionally, the Group continuously develops the integration of medical principles, scientific principles, and the latest technology to further enhance and increase the success rate of conception. In the year 2568 The Group has a pregnancy success rate from ICSI infertility treatment and a pregnancy success rate from ICSI infertility treatment with added embryo genetic testing (NGS) services and the use of PGT-A Plus technology as a tool for detecting genetic abnormalities in embryos before implantation. This innovation can detect polyploidy chromosomal abnormalities. Based on the number of pregnant patients compared to the total number of patients who underwent embryo transfer equal to 66% in 2567 and 25 6 8 Percentage 71 Ta in order

Furthermore, the Group also utilizes the Embryoscope Plus machine, an AI system imported from Denmark, which helps evaluate embryos by assigning scores based on measurable quality and processing by AI. This system has been developed to display various data about embryos and analyze their quality efficiently and accurately. The closed-system embryo incubator helps control temperature, humidity, and the culture medium to maintain optimal conditions. It includes a camera to monitor embryo development 24 hours a day, allowing continuous observation without disturbing the embryos. This technology helps produce highly viable embryos, thereby increasing the chances of pregnancy.

With advanced treatment innovations and expertise combined with the attentive care of its medical team and personnel, along with the selection of the most suitable and best equipment, the Company stands out as a leader in comprehensive infertility treatment.
with a success rate higher than the standard average and continuously increasing success rates.

2. Specialized Personnel

As the Group primarily focuses on successful conception, it places great importance on the capabilities of its medical personnel. The Group is committed to personnel development to elevate them as leaders in medical fertility, along with Embryologist leading in the ASEAN region as of December 31 2568 The Group has a team of doctors Embryologist ( 19 people, including GFC Ubon) and Medical Technologist belonging to the company, full-time, totaling Number 22 people (This number does not include GSM Number 3 C N ) with specialist doctors who have experience and knowledge in obstetrics-gynecology and infertility treatment for more than 24 years, enabling accurate analysis of the causes of infertility and appropriate treatment selection for clients, which will increase the chances of successful pregnancy.

Furthermore, the Group has Embryologist embryologist specialists certified as Embryologist Certificate holders by the Association of Thai Embryologists (ATE). Number 11 cases and CLINICAL EMBRYOLOGY CERTIFICATION from the European Society of Human Reproduction and Embryology (ESHRE). Currently, the Group has Embryologist who passed the certification ESHRE Number 7 cases and doctors who passed ESHRE certification Number 1 cases while Thailand only has 117 cases

Furthermore, the Group continuously emphasizes the training and development of medical personnel to raise awareness of the quality and standards in using various treatment technologies, as well as to monitor the development of new treatment technologies and medical equipment that will always help increase the chances of treatment success. This enables the Group to continuously increase its success rate in conception.

3. Excellent Service Quality

The Group offers excellent service quality and standards. In addition to a team of qualified and attentive doctors and scientists, the Group also possesses efficient and modern tools and equipment that meet international standards. Furthermore, it utilizes data science for collecting and analyzing customer data and internal data storage as a tool to develop more efficient services.

Before providing services each day, the Group's medical personnel must undergo temperature checks and strictly maintain cleanliness according to the Group's operational procedures before starting work, for the safety of all doctors, nurses, and patients.

Furthermore, the Group's sterile operating rooms meet Cleanroom Class 10,000 standards in terms of cleanliness and other standards equivalent to major hospital operating rooms, ensuring international sterility standards. The embryo culture laboratory maintains Class 1,000 cleanliness and is supervised exclusively by specialized scientists, in accordance with standards from the Association of Thai Embryologists (ATE). Additionally, the laboratory has received external quality assessment (EQA) certification from UK NEQAS (United Kingdom National External Quality Assessment Service), an organization that certifies laboratories and conducts external quality evaluations. The Group has received standard certification for both embryology and allosperm analysis. Assessment) to ensure that the quality of the laboratory and the effectiveness of the Group's treatment meet standards benchmarked and evaluated by external organizations from internationally recognized institutions. This demonstrates that the Group's treatment processes, including the storage of embryos, eggs, and sperm, are standardized and safe from pathogens and viruses. Therefore, with the Group's service quality and standards, the Group has continuously increasing patient numbers and treatment success rates.

4. Marketing, Public Relations, and Customer Relationship Strategies

The Group has a clear approach to developing marketing differentiation and building customer loyalty, emphasizing service and communication based on understanding and attentiveness to customer needs. The Company has established a customer relations unit responsible for closely overseeing and coordinating with customers, from providing comprehensive advice, recommendations, and information, to monitoring treatment at every stage, and continuously and timely communicating relevant news.

Furthermore, clients can directly communicate with the team of scientists during the treatment process to better understand complex procedures, fostering trust and a sense of closeness akin to family care, which leads to long-term relationships and opens opportunities for offering new services in the future. In terms of expanding the customer base and building brand awareness, the Group utilizes various online channels as important tools, including Facebook, Line Official, Instagram, TikTok, Twitter, and YouTube, to increase reach to target audiences and facilitate quick information inquiries for clients. Clients can also study preliminary details about infertility treatment services, such as doctor information, treatment guidelines, pros and cons of each method, and estimated costs, to aid in decision-making before receiving services. Concurrently, the Company aims to build the image and credibility of its medical team by regularly organizing live Facebook knowledge-sharing activities about infertility treatment each week, providing an opportunity for interested individuals to ask direct questions, thereby enhancing familiarity, trust, and confidence before deciding to use the services.

For brand awareness and marketing communication strategies, the Group conducts public relations through influencers such as actors, singers, celebrities, and bloggers across various age groups. This is because these influencers have a large following both online and in general society. The Group provides infertility treatment services using ICSI or egg freezing and egg banking. When these influencers achieve success from the services received, they promote the treatment outcomes and their positive experiences with the Group through their various online channels, effectively building brand awareness and widespread credibility. Furthermore, after providing services, the Company evaluates customer satisfaction to analyze additional needs and suggestions for service development. The results of these evaluations are used to improve work processes and enhance service quality, enabling the Company to meet customer needs more quickly, precisely, and efficiently in the future.

Other Information

NameDescription
Service's Responsibility for Information Provision

1. Accuracy and Completeness of Information

Information regarding the treatment process

  • Provide consultation and Explain each treatment method, such as IUI, IVF, ICSI in detail

  • Specify related procedures, including pre- and post-treatment preparation.

Information regarding success rates

  • Disclose the success rates of each method based on relevant factors, such as age and health conditions.

  • Do not provide exaggerated information or create unrealistic expectations for service recipients.

  • Information regarding risks and side effects

Inform about potential risks

  • Explain conditions that may lead to ineffective treatment.

2. Cost Transparency

  • Clearly state service fees through various media and at service points.

  • During the information provision stage for each service, treatment costs for each procedure will be disclosed prior to decision-making.

  • Avoid
    Charging unnecessary fees without prior notification.

    If there are packages or discounts, the conditions should be fully disclosed.

  • If there are packages or discounts Customers will be verified before/upon billing, and Fully disclose the conditions

3. Fair Advertising and Public Relations

  • Use data with standardized and verifiable storage methods.

  • Do not use misleading information for consumers, such as statistics that do not align with reality.

  • If review images or testimonials from service users are used, consent from the data owner should be obtained beforehand.

4. Protection of Service User Privacy: Personal data of service recipients must be protected and not disclosed without authorization.

  • There are procedures for the use and storage of service user data, overseen by the Personal Data Protection Committee. PDPA

  • If any Necessity of using data for treatment referral For research or marketing, notification and consent must always be obtained beforehand.

5. Accountability for Errors

  • If incorrect information is provided
    Corrections must be made and service users informed immediately.

  • Provide channels for service users to file complaints and ensure appropriate problem resolution.

Treatment of Business Competitors
  • directors, executives, managers, and employees conduct themselves within the framework of fair competition.

  • Do not seek confidential information of trade competitors through dishonest or inappropriate means.

  • Do not engage in any actions that may affect the reputation of competitors, such as providing negative information, making accusations, or criticizing without clear facts and reasons.

Throughout the accounting year, 256 8

Customer Satisfaction

The company emphasizes creating positive experiences and enhancing the satisfaction of customers, with a focus on being user-centric. (Customer center) includes providing services according to international standards, coupled with continuous development of customer relationship management, to appropriately and efficiently respond to needs.

In 2025, the company consistently monitored and evaluated customer satisfaction levels, reflecting the quality of service and customer trust in GFC. The company continues to focus on developing comprehensive medical services and consultations to ensure customers receive appropriate and optimal care at every step. GFC prioritizes customer relationship management, focusing on 3 main approaches:

GFC prioritizes customer relationship management, focusing on 3 main approaches:

  • has developed tools for evaluating service recipient satisfaction (Customer Satisfaction Index : CSI) to cover more service dimensions and design Evaluation methods, response to feedback from service recipients, and follow-up systems and collects in-depth data on customer experiences to analyze and continuously improve services. with daily, weekly, and monthly monitoring frequencies.

  • Development of Digital Customer Experience – The company has leveraged digital technology to enhance service delivery.

  • Communication and Comprehensive Information – The company prioritizes transparent and accessible communication through various channels to ensure customers receive accurate information and can make confident decisions.

Evaluation of customer satisfaction for services rendered Branch Rama 3 and Rama 9 International branches

Satisfaction

2023

2024

2025

Target

Actual Performance

Actual

Target

Actual Performance

Actual

Target

Actual Performance

Actual

Customer satisfaction at Rama 3 branch

(Percentage)

90.00

94.98

90.00

96.25

90

98.42

Customer satisfaction at Rama 9 International branch (Percentage)

90

97

Complaint Management Performance

Proportion of complaint channels

GFC Contact Center

Line Official

Website

www.genesisfertility.co.th

Facebook

Material Changes & Developments

Material Changes & Developments

YearDescription
2,016

GFC

Genesis Fertility Center Public Company Limited ("the Company" or "GFC") was established on December 8, 2016, with an initial registered capital of 10.00 million Baht, divided into 1.00 million ordinary shares with a par value of 10.00 Baht per share. It was founded by Assoc. Prof. Dr. Pitak Laokirkkiat and Dr. Pramook Wongthanakiati, holding 35.00% and 25.00% of the shares, respectively, together with 3 other doctors and specialists in assisted reproductive technology who collectively hold 40% of the shares, to provide comprehensive medical services for individuals with infertility issues.

2,017

GFC

  • GFC commenced operations providing medical services for individuals with infertility issues.

  • GFC registered a capital increase from 10.00 million Baht to 30.00 million Baht through the issuance and offering of 2.00 million new ordinary shares with a par value of 10.00 Baht per share for business expansion, allocated proportionally to existing shareholders (

  • GFC received certification for medical assisted reproductive technology services in accordance with the Assisted Reproductive Technology Child Protection Act B.E. 2558 (2015) by the Department of Health Service Support, Ministry of Public Health.

  • GFC registered its business trademark with the Trademark Division, Department of Intellectual Property.

2,019

GSM

Genosomics Company Limited ("GSM"), which is a subsidiary of the Company (the Company currently holds 99.99% of shares), was established on October 1, 2019, with an initial registered capital of 5.00 million Baht, divided into 500,000 ordinary shares with a par value of 10.00 Baht per share. It was founded by GFC to provide genetic material and chromosomal integrity analysis services (Next generation sequencing: NGS).

2,020

GFC

  • GFC registered an increase in its registered capital from 30.00 million Baht to 40.00 million Baht through the issuance and offering of 1.00 million new ordinary shares with a par value of 10.00 Baht per share, for business expansion. These shares were allocated to existing shareholders proportionally (RO).

  • GFC was the first in Thailand to introduce EEVA technology, an artificial intelligence system ("Artificial Intelligence" or "AI system"). The company utilizes this technology to assist in evaluating the quality of embryos for embryo culture in a closed-system embryo incubator (Geri plus) in the company's laboratory.

GFCFG

  • GFC Fertility Group Company Limited ("GFCFG"), a subsidiary of the company (currently 99.99% owned by the company), was established on December 3, 2020, with an initial registered capital of 5.00 million Baht, divided into 500,000 ordinary shares with a par value of 10.00 Baht per share. It was founded by GFC to serve as a holding company for investments in other businesses with the objective of engaging in other activities that generate benefits or support the company's operations, which currently have no commercial revenue.

2,021

GFC

GFC registered a capital increase from 40.00 million Baht to 80.00 million Baht by issuing and offering 4.00 million new ordinary shares at a par value of 10.00 Baht per share, to be used for business expansion through a rights offering to existing shareholders (RO).

2,022

GFC

  • The Extraordinary General Meeting of Shareholders No. 2/2565 held on November 4, 2565, resolved as follows:

    • Approved the conversion from a limited company to a public limited company.

    • Changed the par value from 10.00 baht per share to 0.50 baht per share.

Increased registered capital by 30.00 million baht, from 80.00 million baht to 110.00 million baht, by issuing 60 million new ordinary shares with a par value of 0.50 baht per share for initial public offering (IPO).

GSM

The Board of Directors Meeting No. 5/2565 on October 19, 2565, acknowledged the temporary suspension of GSM's operations from November 1, 2565, to July 31, 2566. Subsequently, the Board of Directors Meeting No. 4/2566 on July 19, 2566, considered and acknowledged the extension of GSM's temporary operational suspension until January 2567, due to the ongoing relocation of its office to the GFC Suvarnabhumi-Rama 9 branch clinic. The clinic is currently undergoing building renovations to accommodate an increase in service users and expand service areas. Embryo genetic testing (NGS) services will, however, be available as usual under GFC.

2,023

GFC

  • Listed on the MAI stock exchange on September 13, 2023, with 110 million registered shares, totaling 220 million baht.

  • The Board of Directors Meeting of Genesis Fertility Center Public Company Limited ("the Company") No. 6/2566, held on November 13, 2023, resolved to approve the Company's investment in a newly established company ("new subsidiary") by establishing one new subsidiary, namely GFC Ubon Company Limited.

2,024

GFC

  • GFCRama9 International has been certified for its standards in providing medical assisted reproductive technology services in accordance with the Assisted Reproductive Technology for the Protection of Children Act B.E. 2567 (2024) by the Department of Health Service Support, Ministry of Public Health.

  • GFC Rama9 International is preparing to commence medical services for individuals facing infertility in B.E. 2568 (2025).

2,024

GFC Ubon

  • GFC Ubon has been certified for its medical assisted reproductive technology services in accordance with the Medical Assisted Reproductive Technology Child Protection Act B.E. 2567 (2024) by the Department of Health Service Support, Ministry of Public Health, and has commenced operations to provide medical services for individuals experiencing infertility.

2,025

GFC

On 21 February 2025 the company commenced operations and held its official opening ceremony ( Grand Opening) Branch GFC Rama 9 International as part of its strategy to expand business into international markets

2,025

GFC Ubon

e on the date 19 January 2568 GFC Ubon Company Limited, a subsidiary of the Company, commenced operations and held an official opening ceremony ( Grand Opening) branch GFC Ubon to expand the service network and increase access to reproductive medicine services at the regional level.

Use of Proceeds from Securities Offerings

Is There Money Raised from a Securities Offering Still to Report On?

No

Commitments Made in the Registration Statement

Are There Commitments or Conditions from an Offering or Listing?

No

Group Operating-Structure Policy

Description

The Board of Directors has established frameworks and mechanisms for overseeing the policies and operations of subsidiaries and other entities in which the Company has made significant investments, considering what is appropriate for the nature, size, and risk level of each entity, to ensure that operations are aligned and consistent with the Company's policies.

The Company consistently monitors the performance of its subsidiaries by holding monthly meetings with them to be informed of their operational results, challenges, and to consider solutions, as well as to oversee that the subsidiaries' operations comply with the company's regulations, laws, and relevant criteria for their business operations.

Companies Where the Company Holds ≥10%

Companies (≥10% Holding)

Company NameAddressProvinceZip CodeTelephoneFaxBusiness TypeSecurity TypeSharesPaid-up Shares
Genosomics Company Limited2292 Rama IX Road, Phatthanakan Sub-district, Suan Luang DistrictBangkok1025002-108-6484Provides genetic material detection and chromosomal integrity testing using Next Generation Sequencing (NGS).Common shares500,000500,000
GFC Fertility Group Company LimitedNo. 2292 Rama 9 Road, Phatthanakan Sub-district, Suan Luang DistrictBangkok1025002-108-6413A Holding Company for expanding investments in other businesses, with the objective of conducting other ventures that generate benefits or support the company's operations.Common shares499,995500,000
GFC Ubon Company LimitedNo. 382 Thepyothee Road, Nai Mueang Sub-district, Mueang Ubon Ratchathani DistrictUbon Ratchathani1040002-229-280002-359-1259The medical and surgical office provides treatment and consultation for infertility, and treats general or specific diseases.Common shares2,999,9985,000,000

Shareholders with Potential Conflict of Interest

Has Potential-Conflict Shareholder (Y/N)

No

Relationships Among Major Shareholders

Relationship Exists (Y/N)

No

Shareholders' Agreement

Agreement Exists (Y/N)

No

Shareholding Diagram (Group Structure)

Does the company hold shares in other companies?

Yes

Subsidiaries

Company NameJuristic Persons / Holders
Genosomics Co., Ltd.Genesis Fertility Center Public Company Limited · Voting rights percent: 99.99 · Shareholding proportion percent: 99.99
GFC Fertility Group Co., Ltd.Genesis Fertility Center Public Company Limited · Voting rights percent: 99.99 · Shareholding proportion percent: 99.99
GFC Ubon Co., Ltd.Genesis Fertility Center Public Company Limited · Voting rights percent: 60.0 · Shareholding proportion percent: 60.0

Income Structure

Product / Service Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenue from operationsTotal revenue from operations352,994.85100371,761.21100354,576.31100
Revenue from infertility treatment services243,075.668.86248,962.8166.97246,047.3169.39
Revenue from embryonic genetic testing services53,697.2815.2168,027.5118.366,93218.88
Revenue from Consultation and Treatment43,845.112.4237,852.6910.1829,122.338.21
Provision of cryopreservation and storage services for embryos, eggs, and embryos10,100.372.8615,110.24.0611,610.673.27
OtherOther2,276.50.641,8080.498640.24

Export Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenueTotal revenue from operations352,994.85100371,761.21100354,576.31100
DomesticDomestic352,994.85100371,761.21100354,576.31100
InternationalInternational000000

Other Income

Operating Other IncomeNon-Operating Other IncomeShare of Profit
1710 · As of year: 1750.03 · Description: Total other income · As of yesteryear: 1384.28 · As of year before yesteryear: 1182.91 · 1711 · As of year: 0.0 · Description: Other income from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.01712 · As of year: 1750.03 · Description: Other income not from operations · As of yesteryear: 1384.28 · As of year before yesteryear: 1182.911713 · As of year: 0.0 · Description: Share of profit · As of yesteryear: 0.0 · As of year before yesteryear: 0.0

Product / Service Characteristics

Introduction

Genesis Fertility Center Public Company Limited ("GFC") operates a comprehensive medical service business for individuals with infertility problems, ranging from providing advice and consultation to selecting appropriate treatment methods, utilizing one of Thailand's most modern reproductive technologies and innovations. This is supported by a team of expert doctors and scientists with experience in reproductive technology, sharing a common goal of fulfilling every family's dream. This commitment drives GFC to design and develop services with understanding, expertise, and meticulous care at every step, starting with diagnosing the causes of infertility using diverse, specific, and appropriate methods for each individual to achieve the most accurate results before proceeding with careful, detailed, and attentive treatment at every stage. Furthermore, all GFC staff are ready to provide consultation on physical and mental readiness to maximize the chances of successful conception. Currently, the company has 3 subsidiaries: Genosomics Co., Ltd. (1) ("GSM"), GFC Fertility Group Co., Ltd. (2) ("GFCFG") and GFC Ubon Co., Ltd. (3) ("GFC Ubon"). The business characteristics of the subsidiaries can be summarized as follows:

1) Genosomics Co., Ltd. ("GSM") operates a business providing embryo genetic testing services (Next generation sequencing: NGS).

GSM is a business promoted for investment in the scientific testing services category, which is a business type classified as important and beneficial to the country. Key benefits received by GSM include an exemption from corporate income tax on net profits derived from promoted business operations for a period of 8 years from the date of commencing revenue generation (from March 16, 2020, until March 15, 2028).

2) GFC Fertility Group Co., Ltd. ("GFCFG") operates as a holding company for investing in other businesses with the objective of engaging in other activities that generate benefits or support the company's operations. It was established on December 3, 2020. Currently, GFCFG has no commercial revenue.

3) GFC Ubon Co., Ltd. ("GFC Ubon") operates a comprehensive medical service business for individuals with infertility problems, ranging from providing advice and consultation to selecting appropriate treatment methods. It was established on December 28, 2023, and has had commercial revenue since August 15, 2024.

Business Type

3114

Business Groups

Business GroupDescription
The Group is one of the leading providers of comprehensive medical services for individuals experiencing infertility in Thailand. The Group's service information

Product and Service Information

Currently, the Group is one of the leading providers of comprehensive medical services for infertility in Thailand. Details of the Group's services are as follows:

1. Initial Consultation Services before Recommendation or Treatment

Before undergoing infertility treatment or pre-conception readiness checks, patients will receive an initial consultation with a specialist in assisted reproductive technology. This is considered the most crucial first step, as the physician will determine the treatment approach, identify causes, and analyze infertility conditions suitable for each couple, or provide recommendations for pre-conception preparation through a detailed medical history and physical examination of both male and female partners to achieve the best treatment outcomes. For initial consultation services before recommendations or treatment, patients will pay on a per-visit basis as determined by the treating physician.

Initial Consultation Service Steps before Recommendation or Treatment

Patients will undergo a pre-conception readiness check by a specialist in assisted reproductive technology. The detailed steps are as follows:

  1. Patients register and create a medical record file. Important documents such as identification cards and marriage certificates will be checked before admitting new patients.

  2. The nurse will assess, inquire, record the history of infertility, and conduct an initial physical examination before the patient sees the doctor, including laboratory analyses such as blood tests and hormone level measurements.

  3. The nurse will inquire about the history of semen analysis results. In cases where the male partner does not yet have such semen analysis results, the nurse will collect semen for examination to assess the quantity, quality, and morphology of the sperm to diagnose the cause of male infertility.

  4. After the initial history taking, the patient will consult with a physician to analyze the causes of infertility. The physician will inquire about symptoms and relevant medical history, along with reviewing previous treatment records.

  5. Physical examination of the female partner, including a per vaginal examination (PV) and transvaginal ultrasound (TVS), to determine the appropriate treatment method for the patient, such as IUI or ICSI.

  6. The nurse will provide consultation and recommend treatment packages as prescribed by the physician. Before undergoing any infertility treatment, all patients must sign a consent form to receive treatment using medical assisted reproductive technology. The treatment procedures, factors affecting success rates, and potential risks or complications will be explained to the patient before consent is given.

  7. The nurse will schedule appointments and issue appointment cards to patients, as well as have patients evaluate their satisfaction with this treatment, to be used for developing and improving service efficiency.

2. Infertility Treatment Services using IUI (Intrauterine Insemination)

Infertility treatment services using IUI (Intrauterine Insemination) involve injecting processed sperm into the female partner's uterus on the day of ovulation to achieve pregnancy without natural intercourse and to increase the chances of successful fertilization. Physicians will consider IUI as the first-line treatment when one or both partners have abnormalities, and it is suitable for younger patients with less severe infertility issues, such as low sperm count or a small cervix. Since IUI does not require surgery or recovery time, the treatment duration is approximately 2 weeks, which is shorter than ICSI. However, IUI infertility treatment has a lower pregnancy success rate compared to ICSI infertility treatment, as it merely involves injecting sperm into the uterus on the day of ovulation, which is a method closer to natural conception. If a patient has abnormalities or falls under the category of infertility, the physician will consider ICSI infertility treatment instead to increase the pregnancy success rate.

Steps for IUI Infertility Treatment Services

After the patient has consulted with a physician for initial consultation services before recommendations or treatment, and the specialist in assisted reproductive technology has determined the IUI infertility treatment approach, the detailed steps for IUI infertility treatment are as follows:

  1. Patients undergo ultrasound examination on the first 1 to 3 days of menstruation to assess suitability for ovarian stimulation.

  2. After ovarian stimulation, the female partner undergoes periodic ultrasound examinations to measure egg size as scheduled by the physician.

  3. The physician diagnoses and determines the ovulation day to schedule the intrauterine insemination. This may involve urine tests to detect ovulation hormones or administering ovulation trigger injections.

  4. On the day scheduled for intrauterine insemination, the male partner accompanies the female partner to provide a semen sample. Ejaculation should be abstained from for 3 to 5 days before the insemination day.

  5. After insemination, one can resume normal activities and daily life.

  6. Approximately 2 weeks after insemination, if the patient's menstruation does not occur, a urine test can be performed to check for pregnancy.

In the year 256 6 - 256 8 The Pregnancy Success Rate from IUI infertility treatment by the Group, calculated from the number of pregnant patients relative to the total number of patients who underwent IUI infertility treatment, is equal to 12.50 percent, 9.61 percent, and percent 13.00 respectively

3. Infertility Treatment Services using ICSI (Intracytoplasmic Sperm Injection)

ICSI (Intracytoplasmic Sperm Injection) infertility treatment involves fertilizing eggs and sperm outside the body until they develop into embryos, by directly injecting a single sperm into an egg to increase the chances of fertilization. This method is often used in cases where the male partner has severe sperm abnormalities or no sperm is detected. ICSI infertility treatment is suitable for couples experiencing infertility, as it helps reduce the risk of fetal abnormalities, making it a highly successful method compared to other infertility treatments and the most popular method currently. The Group has a team of specialized physicians who closely monitor patients in collaboration with a team of expert scientists throughout every case. Additionally, there is a laboratory (LAB) and operating room, along with standardized anesthesia services, with cleanliness equivalent to a major operating room. It also features medical instruments, equipment, materials, and technology certified for standards and safety by the Food and Drug Administration (FDA) for its services. Furthermore, the Group utilizes closed embryo culture technology in an Embryoscope plus incubator, which features an iDA score software system used to analyze embryo images, assign scores, evaluate development, and select the best embryos. This incubator helps control temperature, humidity, and the culture medium to maintain optimal conditions. High-quality microscopic cameras are installed inside the incubator, allowing detailed monitoring of embryo development 24 hours a day. Embryo development can be viewed through high-resolution images. Therefore, this modern technology helps produce highly viable embryos, efficiently and accurately analyze embryo quality, thereby increasing the chances of pregnancy. Customers will pay for services as a package for ICSI infertility treatment, where the treatment package depends on the suitability of each couple as determined by the company's physicians based on their diagnostic guidelines. Preliminary details are as follows:

  1. Treatment Package 1 (ICSI Delight Package) is an introductory package for younger patients (under 37 years old) with hormone levels deemed appropriate by the physician. Most patients in this group have a relatively high number of eggs, and the eggs are of good quality and strong, thus increasing the chances of fertilization and, consequently, the success rate of pregnancy.

  2. Treatment Package 2 (ICSI Package) is a standard package for patients with more challenging cases and health issues as determined by the physician. The number of retrieved eggs will be lower, and the quality and strength of the eggs will be reduced compared to patients from Treatment Package 1. Therefore, the medical team and medical technologists must exercise greater caution and complexity in providing treatment services.

  3. Treatment Package 3 (ICSI Premium Package) is a package for patients with relatively complex cases, who may have health issues or low egg quality and strength. Treatment will be provided by highly experienced and specialized physicians.

    Steps for ICSI Infertility Treatment Services

    After the patient has consulted with a physician for initial consultation services before recommendations or treatment, and the specialist in assisted reproductive technology has determined the ICSI infertility treatment approach, the patient will proceed with the treatment process. The ICSI infertility treatment process can be divided into 3 steps as follows:

    Process 1: Ovarian Stimulation This is a process where the physician considers administering ovarian stimulation injections to obtain eggs of appropriate size. The physician will assess the patient's readiness before ovarian stimulation through ultrasound examination during the first 1 to 3 days of menstruation. Subsequently, the physician will administer ovarian stimulation injections and schedule periodic ultrasound examinations to measure egg size. When the eggs reach an appropriate size, the female partner will receive an ovulation trigger injection, and a date will be scheduled for egg retrieval via the vagina.

    Process 2: Egg Retrieval, Fertilization, and Embryo Culture Once the eggs reach an appropriate size as determined by the specialist physician, on the day scheduled for egg retrieval, the male partner will accompany the female partner to provide a semen sample. The eggs and sperm will then be fertilized to form embryos and cultured in a growth medium to develop into high-quality embryos in the laboratory by specialized embryologists. This process typically takes approximately 5 to 6 days. Embryo culture in the laboratory can be divided into two types: 1. Open culture system, which involves culturing embryos in petri dishes (where the culture medium is in direct contact with the atmosphere in the incubator). 2. Closed culture system in an Embryoscope plus incubator, which features an iDA score software system used to analyze embryo images, assign scores, evaluate development, and select the best embryos. This incubator helps control temperature, humidity, and the culture medium to maintain optimal conditions. High-quality microscopic cameras are installed inside the incubator, allowing detailed monitoring of embryo development 24 hours a day. Embryo development can be viewed through high-resolution images. Therefore, this modern technology helps produce highly viable embryos, efficiently and accurately analyze embryo quality, thereby increasing the chances of pregnancy. However, the closed culture system in the Embryoscope plus incubator is subject to the discretion of the treating physician and incurs additional charges beyond the ICSI infertility treatment package. After the embryos have developed to an appropriate stage, approximately 5 to 6 days, the treating physician will consider the patient's eligibility for preimplantation genetic testing (NGS) based on legal indications as an option for the patient, to analyze embryo abnormalities before transfer to the woman's uterus. This increases the success rate of pregnancy compared to conventional ICSI infertility treatment. Preimplantation genetic testing (NGS) is an optional service with additional costs beyond the ICSI infertility treatment package (please refer to section 2.2.4 Services for Preimplantation Genetic Testing (Next Generation Sequencing: NGS) for more details).

    Process 3: Endometrial preparation and embryo transfer Approximately 5 to 6 days after egg retrieval, viable embryos will be cryopreserved. The female partner will then undergo endometrial preparation for embryo transfer in the next menstrual cycle using hormones. In some cases, the physician may consider and advise certain patients to undergo Endometrial Receptivity Analysis (ERA) before embryo transfer, which is an optional service with additional costs beyond the ICSI infertility treatment package. This diagnostic test aims to identify the optimal window for embryo transfer for each woman, thereby maximizing the chances of successful implantation and pregnancy. Approximately 10 to 14 days after embryo transfer, the female partner will undergo a blood test to check for pregnancy hormones.

In addition, the Group provides other services related to infertility treatment, which are optional services with additional costs beyond the ICSI infertility treatment package. These include oocyte freezing/sperm freezing/embryo freezing and testicular sperm extraction (TESE). All services related to infertility treatment are performed by specialist physicians and scientists in a laboratory with cleanliness equivalent to a major operating room and sterile conditions according to international standards. Details are as follows:

Oocyte freezing / Sperm freezing / Embryo freezing

Oocyte freezing and egg banking for patients undergoing ICSI infertility treatment

This involves collecting eggs obtained from ovarian stimulation, removing them from the body, and cryopreserving them in a laboratory at temperatures below -196 degrees Celsius with an appropriate environment in an internationally standardized laboratory. Eggs can be stored for 5 to 10 years, depending on the quality of each patient's eggs, for future use when ready for pregnancy for subsequent children. Oocyte freezing and egg banking are optional services with additional costs beyond the ICSI infertility treatment package.

Sperm Freezing

This involves collecting sperm obtained from the male partner or through Testicular Sperm Extraction (TESE) outside the body and cryopreserving it in a laboratory at temperatures below -196 degrees Celsius with an appropriate environment in an internationally standardized laboratory, without prior fertilization with an egg to form an embryo. This method is for male partners who wish to store sperm for future use, as they may need to undergo certain radiation treatments, or for male partners considering vasectomy and other medical treatments, including various cancer treatments that may adversely affect sperm quality. These are reasons why male partners may choose to freeze sperm before undergoing treatment.

Embryo Freezing

This is a process that occurs after the fertilization of eggs and sperm and subsequent embryo culture. Strong embryos are then cryopreserved in a laboratory at temperatures below -196 degrees Celsius and in an appropriate environment within an internationally standardized laboratory, before being transferred back to the uterus when the patient is ready for pregnancy. Embryo freezing is an optional service with additional costs beyond the ICSI infertility treatment package.

Testicular Sperm Extraction (TESE)

In cases where the male partner's semen analysis reveals no sperm or no semen at all, often due to blocked sperm ducts or inability to ejaculate, it is necessary to retrieve sperm directly from its source (testicles). The physician will perform a minor surgical procedure to extract sperm from the testicles. This sperm will then be cryopreserved for future use or for subsequent ICSI infertility treatment, which is another method that helps increase the chances of conception.

In the year 256 6 to the year 256 8 The Pregnancy Success Rate from ICSI infertility treatment by the Group, calculated from the number of pregnant patients relative to the total number of patients who underwent embryo transfer, is equal to 70.37 percent, 61.76 percent, and percent 71.22 respectively

4. Services for Preimplantation Genetic Testing (Next Generation Sequencing: NGS)

Preimplantation Genetic Testing (NGS) is the examination of chromosomes or genetic material of embryos using a technique to analyze the number of all 23 pairs of chromosomes to detect abnormalities in embryos before transfer to the woman's uterus. This allows for the selection of embryos free from genetic abnormalities that cause various diseases. Embryo chromosome testing helps select strong and healthy embryos, screen for genetic diseases, and identify embryo abnormalities before implantation, thereby leading to a higher success rate of pregnancy compared to conventional ICSI infertility treatment. However, Preimplantation Genetic Testing (NGS) incurs additional charges beyond the ICSI infertility treatment package.

After the embryos have fully developed, the treating physician will consider the patient's eligibility for preimplantation genetic testing (NGS) based on legal indications (of either the male or female partner), such as the wife being 35 years of age or older, or having medical indications that the embryo may be at risk of genetic abnormalities, recurrent pregnancy loss (two or more consecutive failures in medical assisted reproductive technology services), a history of miscarriage, and one or both partners having genetic abnormalities that could clearly be transmitted to the fetus upon conception.

In the year 2566 to 2568 The Pregnancy Success Rate from ICSI infertility treatment with added Preimplantation Genetic Testing (NGS) services by the Group, calculated from the number of pregnant patients relative to the total number of patients who underwent embryo transfer, is equal to percent 71.30 percent, 70.00 percent, and percent 71.03 T respectively

5. Oocyte Freezing and Egg Banking Services

Oocyte freezing and egg banking involve collecting eggs obtained from ovarian stimulation, removing them from the body, and cryopreserving them in a laboratory at temperatures below -196 degrees Celsius and in an appropriate environment within an internationally standardized laboratory, without prior fertilization with sperm to form an embryo. This is for future use when ready for pregnancy. Eggs can be stored for 5 to 10 years, depending on the quality of each patient's eggs. With oocyte freezing or egg banking, patients do not require recovery time. Service recipients can plan their future pregnancies independently, reduce the risk of infertility, maintain egg quality from deteriorating with actual age, and reduce the risk of chromosomal abnormalities associated with maternal age. Therefore, it has become increasingly popular among clients planning future pregnancies, as women tend to marry or have children later in life, thus increasing the risk of having children with chromosomal abnormalities.

Compliance with laws, standards, licenses, and certifications related to infertility treatment services

The Group operates specialized medical clinics in obstetrics and gynecology, which have complied with laws, treatment standards, and obtained all relevant licenses and certifications. Details are as follows:

  1. Hospital Act B.E. 2541 (and its amendments) by the Department of Health Service Support, Ministry of Public Health. The Hospital Act B.E. 2541 (and its amendments) stipulates that specialized medical clinics must apply for permission and register with the Bureau of Nursing and Medical Arts, Department of Health Service Support, Ministry of Public Health. This requires important details and conditions such as the internal layout of the medical facility, the name of the medical practitioner approved by the Medical Council, and the medical professional license or medical practice license of the physician, etc. The Group has fully obtained these important licenses, including the license to operate a medical facility (S.P.7) and the license to manage a medical facility (S.P.19).

  2. The Protection of Children Born through Medical Assisted Reproductive Technology Act B.E. 2558 was enacted to appropriately define the legal parental status of children born through medical assisted reproductive technology, as well as to control medical scientific research on embryos and medical assisted reproductive technology to prevent misuse. The company fully complies with the said Act and has received standard certification for services related to medical assisted reproductive technology under the Protection of Children Born through Medical Assisted Reproductive Technology Act B.E. 2558 (Form KTP.9) and is under the supervision of the Committee for the Protection of Children Born through Medical Assisted Reproductive Technology (KCTP), which is a committee established to control, inspect, supervise, and set various related policies according to the said Act. It is divided into 6 chapters, which can be summarized as follows:

Chapter 1 Committee for the Protection of Children Born through Medical Assisted Reproductive Technology (KCTP)

which is a committee established to control, inspect, supervise, and set various related policies according to the said Act.

Chapter 2 Services related to Medical Assisted Reproductive Technology

  • The qualifications of this medical practitioner must not include prohibited characteristics and must comply with the standards prescribed by the Medical Council with the approval of the Committee.

  • Before providing services, the service provider must arrange for the examination and assessment of the physical, mental, and environmental readiness of the service recipient as prescribed by the Medical Council with the approval of the Committee.

  • The creation, preservation, utilization, or termination of embryos must be carried out as prescribed by the Medical Council with the approval of the Committee. However, it is prohibited to preserve or utilize embryos older than 14 days from the date of fertilization.

  • The service provider may perform diagnostic genetic testing on potential embryos as necessary and appropriate. This must not be an act that could be understood as sex selection. as prescribed by the Medical Council with the approval of the Committee.

  • Artificial insemination must be performed by a legally married husband and wife.

Chapter 3 Surrogacy

  • Legally married husband and wife who are unable to conceive must be of Thai nationality. In cases where one party is not of Thai nationality, they must be registered. married for at least 3 years

  • The surrogate mother must not be a parent or descendant / must be a blood relative of the said husband or wife. In cases where there are no relatives, another woman may act as a surrogate, provided it complies with the criteria announced by the Minister of Public Health / must be a woman who has previously given birth. If the woman has a legal husband or a man with whom she cohabits as husband and wife, the consent of the legal husband or such man must also be obtained.

  • Surrogacy can be performed in 2 ways: using embryos created from the husband's sperm and/or the legally married wife's eggs (it is prohibited to use the eggs of the surrogate mother and to conduct surrogacy for commercial purposes).

Chapter 4 Paternity and Maternity of Children and Protection of Children Born through Medical Assisted Reproductive Technology

  • The child shall be the legitimate child of the legally married husband and wife who wish to have a child (sperm or egg donors have no rights or duties towards each other under the Civil and Commercial Code).

Chapter 5 Control of Operations related to Medical Assisted Reproductive Technology

  • A medical practitioner who intends to use residual embryos from treatment for research purposes must obtain permission from the Committee. It is prohibited to conduct research on embryos older than 14 days from the date of fertilization (excluding the time of embryo cryopreservation).

  • It is prohibited to insert sperm, eggs, embryos, or any part of such cells into the body of an animal.

  • It is prohibited to buy, offer to buy, sell, import, or export sperm, eggs, or embryos.

  • If the owner of the sperm, eggs, or embryos deposited with the custodian dies, such sperm, eggs, or embryos shall not be used, unless
    Written consent must be given before death and must be used solely for the infertility treatment of the said living husband or wife.

  • If a medical practitioner providing services fails to comply with standards, it shall be considered a violation of medical professional ethics.

Chapter 6 Penal Provisions are in accordance with professional laws, civil and commercial laws, and criminal laws.

  1. Criteria for requesting approval for advertising or announcements related to medical facilities by the Department of Health Service Support, Ministry of Public Health

The Group has complied with laws and announcements related to advertising, and has submitted requests for approval. use Images and texts used in advertisements or announcements from relevant agencies for advertising or announcements via internet media. which is in accordance with the Hospital Act B.E. 2541 (and its amendments), the Notification of the Department of Health Service Support regarding Criteria, Methods, Conditions, and Expenses for Advertising or Announcements related to Medical Facilities B.E. 2562 (and its amendments), and the Operational Manual for Considering Approval of Advertising or Announcements related to Medical Facilities. Furthermore, the Group's Sales and Marketing Director will control and review all advertising messages before public dissemination to ensure that the Group fully complies with all relevant advertising laws.

Research & Development

Has R&D Policy (Y/N)

No

R&D Cost — Label

Research and development (R&D) expenses over the past 3 years (Million Baht)

R&D Cost — This Year

0.0

R&D Cost — Last Year

0.0

R&D Cost — 2 Years Ago

0.0

Assets Used in the Business

Permanent Assets — Description

Details of assets used in business operations

Fixed assets

As of December 31, 2025, the Group has key "fixed assets" used in its operations, with a total net book value of 481.50 million Baht, detailed as follows:

Type / Description of assets

Type of ownership

Net book value (million Baht)

Obligations

1) Land, total area 340 square wah, according to title deeds No. 141373, 141374, 141375, and 141376

Owner

69.60

Mortgaged to secure long-term loans from financial institutions

2) Buildings and internal systems, and building improvements

Owner

324.32

Mortgaged to secure long-term loans from financial institutions

3) Medical instruments and medical equipment

Owner

70.46

Pledged to secure overdraft facilities from financial institutions

4) Furniture and office equipment

Owner

15.46

None

5) Vehicles

Owner

1.46

None

6) Assets under installation

Owner

0.20

None

Total

481.50

Right-of-use assets

As of December 31, 2025, the Group has right-of-use assets with a net book value of 23.26 million Baht, detailed as follows:

Version 1 Lease agreement for use as the company's office space (Rama 3 Clinic Branch)

Type of lease agreement

Lease agreement (Rama 3 Clinic Branch Lease Agreement Version 1)

Tenant

Company

Lessor

Non-related legal entities of the company

Leased premises

  1. Building No. 924/2 Rama 3 Road, Bang Phong Phang Sub-district, Yannawa District, Bangkok
    (Including additional area)

  2. Sub-building, 1st to 3rd floors, total area 399 square meters, located at No. 924 Rama 3 Road
    Bang Phong Phang Sub-district, Yannawa District, Bangkok

  3. The tenant provides 3 parking spaces for the lessee at the back of the building, available at all times.

Usable area

Approximately 1,278 square meters

Purpose

For use as the company's office space (Rama 3 Clinic Branch)

Service rate

  1. For April 2023 to May 2023, the monthly rent is 521,200 Baht
    (Excluding VAT)

  2. For June 2023 to March 2026, the monthly rent is 547,260 Baht
    (Excluding VAT)

  3. For April 2026 and May 2026, the monthly rent is 547,260 Baht
    (Excluding VAT)

  4. For June 2026 to May 2027, the monthly rent is 573,320 Baht
    (Excluding VAT)

To guarantee that the tenant will fully comply with this agreement throughout the lease term, on the date of this agreement, the tenant has deposited a security deposit of 1,526,760 Baht with the lessor. In the event that the tenant fully complies with this agreement throughout the lease term, the lessor will return the full security deposit to the tenant without interest upon termination of the lease agreement, once the tenant has delivered and the lessor has received the leased building in good order.

Version 2 Lease agreement for use as a subsidiary's office space

Type of lease agreement

Lease agreement (Subsidiary's lease agreement)

Tenant

Genosomics Co., Ltd. (Subsidiary)

Lessor

Non-related legal entities of the company

Leased premises

The company's office building at the back (partially), No. 924 Rama 3 Road, Bang Phong Phang Sub-district
Yannawa District, Bangkok

Usable area

95.09 square meters

Purpose

To provide genetic material analysis and chromosomal integrity testing services (NGS)

Duration

April 1, 2023 to May 31, 2027 (4 years 2 months)

Service rate

  1. For April 1, 2023 to May 31, 2023, the monthly rent is 38,036 Baht
    (Excluding VAT)

  2. For June 1, 2023 to March 31, 2026, the monthly rent is 39,937 Baht
    (Excluding VAT)

  3. For April 2026 and May 2026, the monthly rent is 39,937 Baht
    (Excluding VAT)

  4. For June 2026 to May 2027, the monthly rent is 41,839 Baht
    (Excluding VAT)

Version 3 Lease agreement for use as a subsidiary's office space

Type of lease agreement

Lease agreement (Subsidiary's lease agreement)

Tenant

GFC Ubon Co., Ltd. (Subsidiary)

Lessor

Related parties of the company

(Ms. Thitima Chaisrisawatsuk and Mr. Rojjanin Chaisrisawatsuk)

Leased premises

Subsidiary's office building, No. 382 Thepyothi Road, Nai Mueang Sub-district, Mueang Ubon Ratchathani District, Ubon Ratchathani Province

Usable area

1,511.955 square meters

Purpose

For use as a subsidiary's office space

Duration

August 15, 2024 to August 14, 2034 (10 years)

Service rate

  1. For August 15, 2024 to August 14, 2027, the monthly rent is 167,000 Baht
    (Excluding VAT)

  2. For August 15, 2027 to August 14, 2030, the monthly rent is 198,444 Baht (excluding VAT)

  3. For August 15, 2030 to August 14, 2033, the monthly rent is 208,366 Baht (excluding VAT)

  4. For August 15, 2033 to August 14, 2034, the monthly rent is 218,784 Baht (excluding VAT)

Version 4 Lease agreement for use as a subsidiary's office space

Type of lease agreement

Lease agreement (Subsidiary's lease agreement)

Tenant

GFC Ubon Co., Ltd. (Subsidiary)

Lessor

Related parties of the company

(Ms. Thitima Chaisrisawatsuk and Mr. Rojjanin Chaisrisawatsuk)

Leased premises

Subsidiary's office building, No. 382 Thepyothi Road, Nai Mueang Sub-district, Mueang Ubon Ratchathani District, Ubon Ratchathani Province

Usable area

229.99 square meters

Purpose

For use as a subsidiary's office space

Duration

August 15, 2025 to August 14, 2034 (8 years 11 months)

Service rate

  1. For September 15, 2025 to September 14, 2027, the monthly rent is 28,750 Baht (excluding VAT)

  2. For September 15, 2028 to September 14, 2031, the monthly rent is 30,188 Baht (excluding VAT)

  3. For September 15, 2031 to August 14, 2034, the monthly rent is 31,697 Baht (excluding VAT)

-

Intangible Assets — Description

Intangible Assets

As of December 31, 2025, the Group has net intangible assets, namely computer software, totaling 2.78 million Baht.

1. Trademarks

The Group has registered trademarks with the Department of Intellectual Property, Ministry of Commerce, as follows:

Trademark

Registration Number

Registration Date

Product Type

191109251

October 17, 2017

Goods Class 44:
Medical Clinic

2. License to operate a medical facility (Rama 9 Branch)

Licensing Authority: Department of Health Service Support, Ministry of Public Health

Licensee: Genesis Fertility Center Public Company Limited

Expiry Date: December 31, 2033

Key details of the license: Authorizes the operation of a medical facility that does not admit inpatients.

Name of medical facility: GFC Genesis Fertility Specialized Medical Clinic in Obstetrics-Gynecology, with additional services provided.

namely large operating rooms

3. License to operate a medical facility (Rama 3 Branch)

Licensing Authority: Department of Health Service Support, Ministry of Public Health

Licensee: Genesis Fertility Center Public Company Limited

Expiry Date: December 31, 2026

Key details of the license: Authorizes the operation of a medical facility that does not admit inpatients.

Name of medical facility: GFC Genesis Fertility Specialized Medical Clinic in Obstetrics-Gynecology, with additional services provided. namely large operating rooms

4. License to operate a medical facility (Rama 9 Branch)

Licensing Authority: Department of Health Service Support, Ministry of Public Health

Licensee: Dr. Chompunuch Chantharakrawee

Expiry Date: December 31, 2027

Key details of the license: Authorizes operation at the medical facility named GF Genesis Fertility Specialized Medical Clinic.

Obstetrics-Gynecology. Type of medical facility: Specialized medical clinic in Obstetrics-Gynecology.

5. License to operate a medical facility (Rama 3 Branch)

Licensing Authority: Department of Health Service Support, Ministry of Public Health

Licensee: Dr. Parawan Tangtham

Expiry Date: December 31, 2026

Key details of the license: Authorizes operation at the medical facility named GF Genesis Fertility Specialized Medical Clinic.

Obstetrics-Gynecology. Type of medical facility: Specialized medical clinic in Obstetrics-Gynecology.

As of December 31, 2025, the Company has secured loan agreements with a financial institution, which have not yet been drawn down, with a total credit facility of 103 million Baht, divided into a long-term loan facility of 86 million Baht, an overdraft facility of 10 million Baht, and a bank guarantee issuance facility of 7 million Baht.

7. Insurance Policies

Property All Risks Insurance Policy consists of:

Contracting Party: Bangkok Insurance Public Company Limited

Insured Location: Genesis Fertility Center Public Company Limited

2292 Soi Chumchon Hua Mak Ko Klang, Motorway Parallel Road, Suan Luang Subdistrict, Suan Luang District, Bangkok

Coverage: Property All Risks Insurance Policy

Period: March 20, 2025 to March 20, 2026

Insured Property: Factory and office buildings (excluding foundations), including renovated and extended parts of buildings, fences, and walls.

Gates, including various utility systems, furniture, fixtures, various electrical appliances and equipment, various office appliances and equipment, including car lifts, and other accessories, and one 6-seater electric golf cart, including lithium batteries and charger.

Total Sum Insured: 321,757,500 Baht

Contracting Party: Muang Thai Insurance Public Company Limited

Insured Location: Genesis Fertility Center Public Company Limited

924, 924/2 Rama 3 Road, Bang Phong Phang Subdistrict, Yan Nawa District, Bangkok

Coverage: Property All Risks Insurance Policy

Period: September 30, 2025 to September 30, 2026

Insured Property: Buildings, structures (excluding foundations), furniture, fixtures, equipment, tools.

appliances, all types of medical supplies, inventory of all types of medicines, medical supplies, chemicals (excluding live stock such as blood, stem cells, etc.)

Total Sum Insured: 121,000,000 Baht

Contracting Party: Muang Thai Insurance Public Company Limited

Insured Location: Genosomics Company Limited

924 Rama 3 Road, Bang Phong Phang Subdistrict, Yan Nawa District, Bangkok

Coverage: Property All Risks Insurance Policy

Period: September 30, 2025 to September 30, 2026

Insured Property: Buildings, structures (excluding foundations), including glass that is part of the building, and renovated additions to the building, fences, gates, walls, electrical systems, plumbing systems, air conditioning systems, communication systems, including systems

basic utilities, furniture, fixtures, office equipment, computers

equipment, tools, appliances, all types of medical supplies

Total Sum Insured: 2,438,674 Baht

Contracting Party: Bangkok Insurance Public Company Limited

Insured Location: GFC Ubon Company Limited

382 Thepyothi Road, Nai Mueang Subdistrict, Mueang Ubon Ratchathani District, Ubon Ratchathani Province

Coverage: Property All Risks Insurance Policy

Period: July 23, 2025 to July 23, 2026

Insured Property: Buildings (excluding foundations), including decorative additions and renovations to the building, parking lots, gates, fences, guardhouses, furniture, fixtures, electrical appliances, computer systems, elevator systems, and various equipment located at the insured premises, utility systems such as electrical systems, generators, transformers, plumbing systems, air conditioning systems, air conditioners, telephone systems, security systems, CCTV, alarm systems, fire extinguishing systems, sanitation systems, satellite reception systems, lightning rods, and various systems used in business operations, and inventory, chemical reagents.

Total Sum Insured: 83,000,000 Baht

8. Details of asset valuation items

The Company engaged an independent asset appraiser, a company approved by the Securities and Exchange Commission, to act as an independent appraiser ("Independent Appraiser") to appraise the value of the assets being traded, to determine a fair price, and for public purposes. The appraisal was conducted using the Market Comparison Approach, with details as follows:

Item

Appraisal Report Date

Appraiser

Location

Area

Owner

Appraisal Date

Summary of Appraised Value

Land, including 4 title deeds: land title deeds no. 141373, 141374, 141375, and 141376, with structures, for operating a medical clinic.

October 7, 2022

Company

Sasipak Co., Ltd.

No. 2292 (Super 9 Building), Motorway Frontage Road (Bangkok-Chonburi/Highway 7), Phatthanakan Subdistrict, Suan Luang District, Bangkok

0-3-40 rai or 340 square wah 40 rai or 340 square wah

Super 9 Company Limited

October 4, 2022

243,016,000 Baht

Has Subsidiaries Investment Policy (Y/N)

Yes

Subsidiaries Investment Policy — Description

Genesis Fertility Center Public Company Limited (the "Company") has a policy to invest in businesses similar to its core business, or related, closely aligned, or beneficial businesses that support the Company's operations, in order to enhance the Company's stability and performance. The Company will carefully analyze project feasibility and consider investment risks, returns, and the Company's financial liquidity. Furthermore, the Company's investments must be approved by the Board of Directors and the shareholders' meeting in accordance with the defined approval authority, and must comply with the regulations and announcements of the Capital Market Supervisory Board, the Securities and Exchange Commission, and the Stock Exchange of Thailand, as well as all relevant laws. The Company will oversee these investments by appointing directors and/or executives of the Company to serve as directors in proportion to its shareholding, in order to control the direction and management policies to align with the Company's business operations.

Investment Policy

The Company has established an investment policy in line with its vision and strategic plan to support the growth of its core business, increase its profitability potential, or invest in businesses that provide synergy to the Company, with details as follows:

  1. Investment in businesses with the objective of conducting business similar to the Company's core business or related businesses shall be carried out under the Company.

  2. Investment in businesses with the objective of conducting other businesses that generate benefits or support the Company's operations shall be carried out under its subsidiaries.

  3. The Company's investment proportion will be determined based on factors related to marketing, brand, administration and management systems, profitability, and the Company's bargaining power.

Operational Oversight Policy

The Company has established an operational oversight policy to define both direct and indirect measures and mechanisms, enabling the Company to effectively oversee and manage its operations. The Board of Directors is responsible for overseeing management and operations to ensure alignment with the Company's goals, business growth direction, and strategic plan, including compliance with public company laws, the Civil and Commercial Code, securities laws, and other relevant laws, as well as announcements, regulations, and various related criteria of the Capital Market Supervisory Board, the Securities and Exchange Commission, and the Stock Exchange of Thailand, all to safeguard the Company's investment interests, with details as follows:

  1. The Company will consider appointing individuals to represent the Company as directors, executives, or controlling persons, in proportion to the Company's shareholding, to oversee that the entities operate in compliance with laws, good corporate governance policies, and other Company policies. However, the appointment of the Company's representatives as directors in each subsidiary and associate must be considered and approved by the Board of Directors' meeting, taking into account the suitability of each company.

  2. If any transaction or operation by a subsidiary falls under the acquisition or disposition of assets as per the relevant announcement on acquisition or disposition of assets, or a connected transaction as per the relevant announcement on connected transactions, which requires the Company to seek approval from the Company's Board of Directors' meeting and/or the Company's shareholders' meeting and/or relevant legal authorities before entering into such transaction, the subsidiary may only enter into such transaction or operation after receiving approval from the Company's Board of Directors' meeting and/or the Company's shareholders' meeting and/or relevant authorities (as the case may be).

Any connected transactions between the Company and the invested entities must be based on business rationale and conducted at market prices with clear and justifiable principles. Furthermore, the Company must ensure that such transactions are disclosed in the financial statements every time, in accordance with the Company's auditing standards on the Stock Exchange. The Company will disclose information of related parties from both sides to prevent potential conflicts of interest.

Furthermore, in the event that an invested entity enters into a transaction, or if certain events occur at an invested entity that require the Company to disclose information to the Stock Exchange of Thailand according to the criteria set by the SET Board, the representative director of such invested entity is obliged to immediately notify the Company's management upon learning of the plan to enter into the transaction or the occurrence of such event.

  1. The directors and executives of the invested entities have a duty and responsibility to disclose information regarding their financial position and operating results to the Company. It is stipulated that relevant announcements of the Capital Market Supervisory Board and the Stock Exchange of Thailand Board shall apply mutatis mutandis. This includes disclosing and submitting information on their own interests and those of related persons, or transactions that may give rise to conflicts of interest, to the Board of Directors, and avoiding transactions that may create such conflicts of interest.

  2. The Company will establish necessary plans and operations to ensure that the invested entities disclose information regarding their operating results and financial position to the Company. The Company will take necessary actions and monitor its subsidiaries and associates to ensure they have adequate and appropriate disclosure systems and internal control systems for their business operations.

In addition, the Company will closely monitor the performance and operations of such invested entities and present analysis results, including opinions or recommendations, to the Board of Directors and the board of directors of the respective invested entities, to be used in considering policy formulation or improving and promoting the continuous development and growth of the invested entities' businesses.

Marketing Policy & Competition

Reporting Mode

3117

Marketing Policy (Overall)

Pricing Policy

Pricing of infertility treatment services

The Group has a pricing policy based on cost-plus pricing to enable the determination of profit margins, close monitoring of profitability, and continuous adaptation to cost structures. Furthermore, the Group has a policy to Choose to compete on value for money As the customer group is relatively less sensitive to price, they prioritize the quality of service over price, allowing the Group to consistently maintain the quality and standards of its services without having to consider price competition, and differentiating itself from other competitors in the market.

Customer Characteristics and Target Groups

The Group's customer base includes both domestic and international customers, who are working-age individuals with an average age of 30 years and above, and have medium to high income levels, or are customers who desire to have children. This customer group is relatively less sensitive to price and economic fluctuations, allowing the Group to consistently maintain the quality and standards of its services without having to consider competition based on value for money. The aforementioned customer groups can be divided into 4 categories:

1. Customers planning to have children in the future

Customers planning to have children in the future are those who receive egg freezing and egg banking services from the Group. This is because, currently, women are increasingly planning for future childbearing, leading to a greater preference for egg banking. This customer group can plan for future childbearing independently, reduce the risk of infertility, and mitigate the risk of chromosomal abnormalities associated with maternal age.

2. Thai couples interested in having children

3. Thai-foreign couples interested in having children

4. Foreign couples interested in having children

Overall, the Group's main customer base is domestic customers. In the year 2023 until the year 2025 The Group has domestic customers who use its services, accounting for a percentage of 97.00 percent, 95.50 percent and percentage 81 .32 respectively, and international customers account for 3.00 percent, 4.50 percent. and percentage 18.68 respectively.

The main customer group of the Group consists of Thai couples interested in having children. In the year 2023 until the year 2025
The Group has a number of Thai couples interested in having children.
(2) receiving treatment with the company. accounting for a percentage of 72 percent, 75.12 percent and percentage 76 of the total number of patients, respectively. followed by customers planning to have children in the future. (1) equal to 17.00 percent, 4.10 percent and 7 percent of the total number of patients. respectively, and Thai-foreign couples interested in having children. (3) with a pro- portion 8.00 percent, 12.52 percent and percentage 10 of the total number of patients, respectively. The remaining patients are foreign couples interested in having children. (4) equal to 3.00 percent, 3.61 percent and percentage 7 of the total total number of patients, respectively.

Marketing and Competition

We are a leader in reproductive technology with over two decades of experience. Built on the expertise of our team of obstetrician-gynecologists and embryologists with over 24 years of experience, the Group is committed to reinforcing its leadership in the infertility treatment market. Various strategic plans have been established to enhance long-term competitiveness and maintain leadership in the market related to comprehensive medical services for infertility, utilizing modern reproductive innovations and technologies, making us one of Thailand's leading providers. Details of the Group's competitive advantages and business strategies have been mentioned above.

Sales and Distribution Channels

  1. Customers contacting directly (Walk-in)

Customers can inquire for information directly at the clinic or contact the Group's phone number.
to inquire about preliminary information regarding infertility treatment services and to schedule appointments with doctors. Due to the Group's reputation and success rates in pregnancy and infertility treatment services, customers engage in word-of-mouth referrals, leading to the Group becoming widely known in the infertility treatment industry. This provides the Group with opportunities to expand its customer base and offer its services more broadly.

2. Customers contacting through social media channels such as Facebook, Instagram, TikTok, Line official, and YouTube, etc.

The Group focuses on proactive marketing through online platforms, which serve as primary communication channels. In the current era of communication, most customers continuously inquire for information through online channels from the Group's various social media platforms such as Facebook, Instagram, TikTok, Line official, and YouTube, etc. This method of inquiry is convenient and fast. Additionally, customers can research and inquire about preliminary information regarding infertility treatment services before receiving treatment, such as researching reputable doctors, studying treatment methods, including the advantages and disadvantages of each treatment method, and studying preliminary prices to aid in decision-making. Furthermore, these online channels are important marketing tools that enable the Group to effectively reach target customer groups, advertise to specific customer segments, and disseminate information to a diverse range of customers.

Industry & Competition (Overall)

Industry Overview

The group of companies operates businesses providing consultation and infertility treatment services using appropriate methods and technologies, such as IUI IVF or IVF/ICSI) including embryo genetic testing services ( Next generation sequencing: NGS) and comprehensive medical services related to infertility. Therefore, the analysis of factors that may affect the group of companies' future operations can be considered from Thailand's economic growth trends and the business growth trends of the group of companies, namely the business of providing infertility treatment services using methods such as IUI The business of providing infertility treatment services using methods such as ICSI and businesses providing embryo genetic testing services ( NGS) including government policy announcements that affect the operations of the group of companies.

Trends in Infertility Treatment Service Business

  • Thailand's infertility treatment service market is projected to grow by 6.2% in 2025 from 2024, reaching a value of over 6.3 billion baht. in line with the increasing demand for services from both Thai and foreign nationals, consistent with global trends.

  • In 2025, the market value for Thai service recipients is expected to expand by 5.0%. Due to the trend of having children later in life and increasingly complex fertility issues, often originating from males, there is a greater reliance on higher-cost treatment methods. Meanwhile, the market value for foreign service recipients is expected to expand by 7.6%, driven by competitive pricing, outstanding service quality, and business expansion into new markets.

Infertility Treatment Service Supply Chain: Thailand is considered a prominent country in providing infertility treatment services due to its high success rate in achieving pregnancy (Success Rate) of approximately 40-70%. Service providers are divided into two main groups:

  1. Treatment group, such as public and private hospitals and clinics, which mostly offer comprehensive services ranging from consultation, assisted reproductive technology treatment, and egg/sperm freezing or storage.

  2. Testing group that provides genetic abnormality screening services. The market value of Thailand's infertility treatment services is divided into 55% for Thai nationals and 45% for foreigners.

Note:

Certain treatment service providers, such as hospitals and large clinics, may also offer genetic screening services for abnormalities. This may be conducted either through in-house laboratory investments or through business partnerships with genetic screening centers.

*The analysis presented in this article covers only the treatment service segment.

Source: Compiled by KASIKORN Research Center

Global Infertility Treatment Service Market Trends

In 2025, the global infertility treatment service market is projected to be valued at over 22 billion USD, growing by 6.8% from 2024.

The global infertility treatment service market continues to grow, led by In Vitro Fertilization (IVF) treatment services, which account for over 80% of the global infertility treatment market value. Particularly in the Asia-Pacific region, the market share for IVF treatment is expected to increase from 22% in 2020 to 26% in 2030, as several countries experience more severe aging societies.

The declining fertility rate, coupled with fertility issues, is a major supporting factor driving the continued expansion of the global infertility treatment service market.

The global fertility rate has shown a continuous decline, from 4.8 children per woman in 1970 to just 2.2 children in 2025. (Figure 3) including changing values regarding childbearing, leading couples worldwide to have children later in life. This is reflected in the gradually increasing average age for first births, currently around 28 years. This trend has led to the infertility treatment service market playing a more significant role. Furthermore, the increasing prevalence of fertility issues globally supports the expansion of international travel for infertility treatment (Fertility Tourism). In 2023, it held the 3rd largest market share, approximately 14% of the global medical tourism market value. The growth of the global Fertility Tourism market is expected to benefit Thailand, as more foreigners travel to receive infertility treatment services.

Trends in Thailand's Infertility Treatment Service Market

In 2025, Thailand's infertility treatment service market is projected to be2 valued at over 6.3 billion baht, growing by 6.2% from 2024 (Figure 4). It is divided into two main groups: Thai customers, accounting for 70% of all service users, and foreign customers, accounting for the remaining 30%.

Although the market value in 2024 is expected to show slower growth due to a high base from the previous year, influenced by the preference for births in the Year of the Dragon, the market value in 2025 is projected to accelerate its expansion.

Thai Infertility Treatment Service Market

The market value for Thai nationals receiving infertility treatment services is expected to grow by 5.0% in 2025, driven by the trend of having children later in life and fertility issues.

The market value of Thai nationals, accounting for over 55% of the total market value, continues to grow due to changing economic and social conditions. This has led Thai couples to prefer having children later in life, reflected in the increasing proportion of births to women aged 30 and above. This proportion, which was around 35% in 2012, is expected to rise to 46% in 2025 (Figure 5). Additionally, many couples experience infertility due to health issues such as hormonal imbalances, obesity, and work-related stress.

High-cost ICSI in vitro fertilization treatment is gaining popularity among Thai service recipients, as infertility causes are becoming more complex and increasingly originate from males.

Infertility treatment using Intrauterine Insemination (IUI) is becoming less popular, reflected by the post-COVID period where the proportion of IUI treatment cycles decreased from 31% in 2022 and is expected to be only 28% in 2025 (Figure 6). Similarly, conventional In Vitro Fertilization (IVF) treatment cycles show an average annual growth rate of only 2%, whereas Intracytoplasmic Sperm Injection (ICSI) treatment has an average annual growth rate of 8% (CAGR 2022-2025).

The growing trend of ICSI treatment aligns with industry operators who indicate that in recent times, infertility among Thai couples has become more complex and is increasingly found to originate from males due to sperm abnormalities caused by risk behaviors such as smoking, alcohol consumption, and disorders resulting from the use of certain medications. Innovative ICSI treatment offers a higher success rate than other methods for patients with the aforementioned conditions.

Foreign Infertility Treatment Service Market

The market value of foreigners traveling for infertility treatment services is expected to grow by 7.6% in 2025.

Thailand also has advantages in terms of price and quality of service. The foreign market value, accounting for over 45% of the total market value, continues to grow, driven by service recipients from China, India, and ASEAN countries who prefer to travel to Thailand for infertility treatment. Thailand is considered one of the main destinations for infertility treatment services due to its outstanding features in Fertility Tourism, including


  • Medical treatment costs are still lower than competitors. The average cost of IVF treatment in Thailand is approximately 6,000 USD, which is lower than key competing countries such as Singapore and Malaysia. including Thai medical facilities that meet Joint Commission International (JCI) standards, which are higher than those in many other countries. (Figure 7)

  • Availability of various facilities which enhances the experience for foreigners beyond treatment, such as hotels/accommodations, restaurants, various shopping centers, and the issuance of Medical Treatment Visas for foreign service recipients who need to reside in Thailand to follow up on their treatment.

The group of foreign service recipients remains a potential market, reflected by businesses focusing on marketing to attract more customers from this group.

The number of foreign service recipients continues to grow, partly due to the Thai infertility treatment service business focusing on offline and online marketing, or through agents, over the past 1-2 years to attract more foreigners to receive services in Thailand. The cost of infertility treatment for foreigners is approximately double that for Thais, as additional supplementary services (interpreters, transportation, commission, etc.) are included in the treatment package. Therefore, expanding into new markets reflects an opportunity for businesses to generate additional revenue, especially for private hospitals, which derive approximately 20-30% of their total revenue from foreigners, presenting future opportunities for the infertility treatment service business.

  • China's relaxed birth policy from 2 children to 3 children since 2021, in response to China's increasingly severe aging society problem and the continued decline in China's population since 2022. It is expected that the Chinese government will continue this policy in the medium to long term. This will likely provide continuous benefits to Thailand, which is one of the main destinations for Chinese nationals seeking infertility treatment services, as domestic services in China are still insufficient to meet the growing demand.

  • Preparation for amending Thailand's surrogacy law such as allowing blood relatives of the wife aged 20-40 to donate eggs without being married, and allowing wives aged 55 and above to receive surrogacy services. If these amendments are successful, they are expected to further support the growth of the assisted reproductive technology infertility treatment market for Thai people. However, the details of these legal amendments still need to be monitored to determine how much they will benefit the infertility treatment service market.

  • Enforcement of the Equal Marriage Act in 2025 This necessitates amendments to various subordinate laws to align with the Equal Marriage Act, particularly allowing same-sex couples to have children through assisted reproductive technology. This is expected to positively impact Thailand's infertility treatment service market by making it more inclusive, extending to the LGBTQ+ community, which currently numbers approximately 5.9 million people in Thailand.

  • Reference from LGBTQ+ report: diverse and inclusive, to promote gender equality, according to the Office of the National Economic and Social Development Council, or accounting for 9% of the total Thai population, and this number is expected to continue increasing in the future.

  • The "have children when ready" trend drives global growth in egg freezing/storage services. This is reflected in the global egg freezing/storage service market value, which is projected to grow at an average annual rate of 8% (CAGR 2023-2028), higher than the growth rate of other services in the infertility treatment market. This could allow Thailand to compete more effectively in the Fertility Tourism market due to less stringent regulations compared to some competitors. For example, Singapore sets the age range for women receiving services between 21-37 years, and Malaysia stipulates that single women who wish to freeze/store eggs must not be Muslim.


Note:

  1. Reference from Technavio's Global Medical Tourism Market report 2024-2028. Medical Tourism primarily involves travel for medical treatment services, excluding massages, spa treatments, and health food, etc.

  2. Market value is assessed based on three assisted reproductive technology treatment methods: Intrauterine Insemination (IUI), In Vitro Fertilization (IVF), and Intracytoplasmic Sperm Injection (ICSI), which involves selecting the strongest single sperm for IVF.

  3. Reference from research report by Kasikornthai Company Limited

Competitive Landscape and Competitors

Companies in Thailand that operate businesses similar to the group of companies.

Company Name

Revenue from Sales and Services (Million Baht)

Business Overview

2023

2024

2025

Genesis Fertility Center Public Company Limited

Business characteristics

  • Initial examination

  • IUI

  • ICSI

  • NGS

  • Egg freezing and storage services

354.58

371.76

352.99

Provides comprehensive medical services for individuals with infertility issues, from offering advice and consultation to selecting appropriate treatment methods, by a team of experienced medical doctors and scientists specializing in assisted reproductive technology.

Companies listed on the SET and mai stock exchanges that operate businesses similar to the group of companies.

Ekachai Medical Care Public Company Limited

(EKH)

Business characteristics

  • Initial examination

  • IUI

  • ICSI

  • NGS

  • Egg freezing and storage services

1,208.60

1,306.89

1,239.62

Operates a medical facility that admits overnight patients, in the nature of a general hospital, and Provides comprehensive medical services for individuals with infertility issues.

Safe Fertility Group Public Company Limited

Business characteristics

  • Initial examination

  • IUI

  • ICSI

  • NGS

  • Egg freezing and storage services

667.11

830.13

701.92

Infertility clinic business, providing consultation for obstetric-gynecological and infertility issues, infertility treatment services using IUI and ICSI methods, embryo genetic testing services (NGS/PGD/PGS), and egg/embryo freezing services.

Inspire IVF Public Company Limited

Business characteristics

  • Initial examination

  • ICSI

121.55

105.70

61.87

Provides medical infertility treatment services using assisted reproductive technology, from consultation to appropriate treatment, by a team of experienced medical doctors and scientists specializing in assisted reproductive technology.

Note: Data as of March 16, 2026.


Procurement of Products & Services

Reporting Mode

3117

Procurement (Overall)

Procurement of medical supplies, pharmaceuticals, medical materials, and medical equipment

The Group manages the procurement of medical supplies, pharmaceuticals, medical materials, and medical equipment to ensure sufficiency for use, based on usage statistics. It also has an efficient ordering system and inventory management to estimate each order, which ensures sufficient stock without over-ordering. To date, the Group has not experienced any shortages of such products and equipment. For the years 2023 to 2025, the Group procures pharmaceutical products, medical supplies, and laboratory reagents from two major distributors. These are leading global companies specializing in the distribution of pharmaceutical products, medical supplies, and medical instruments and equipment of international quality and standards. They have consistently demonstrated strong operational capabilities, and the Group has never encountered any issues with orders from these distributors.

Raw Material Acquisition (Overall)

Procurement of Physicians and Medical Personnel

The Group places great importance on the selection of physicians and specialized medical personnel, as medical professionals are crucial resources and the core of its operations. The selection process for all medical personnel within the Group involves a thorough verification of qualifications and professional documents before employment to ensure compliance with relevant standards and the requirements of the Ministry of Public Health. The Group employs medical personnel in both permanent and temporary capacities. Permanent physicians work more than 40 hours per week, while temporary physicians work less than 40 hours per week. Permanent medical technologists work according to normal working hours, and temporary medical technologists work after hours or assist in urgent blood test laboratory tasks. These medical personnel receive professional fees according to the company's established structure. As of December 31, 2023, to December 31, 2025, the Group has the following physicians and medical personnel:

Position

December 31, 2023

December 31, 2024

December 31, 2025

Permanent

Temporary

Permanent

Temporary

Permanent

Temporary

Physicians

3

11

5

2

6

5

Nurses

10

3

11

1

23

8

Nursing Assistants

2

4

3

0

4

0

Scientists or

Medical Technologists

25

3

19

2

19

0

Total

40

21

38

5

52

13

The Human Resources Department is responsible for recruiting employees through various channels, including the Group's website, job search websites, social media for physicians and scientists specializing in reproductive technology, and referrals from existing employees within the Group. Additionally, the company's executives maintain good relationships with specialized physicians and scientists, which serves as another important channel for widely accessing such personnel.

Furthermore, the Group recognizes the importance of medical personnel, as well as the development of personnel and the maintenance of operational standards. Therefore, the Group has prepared a plan for personnel development, including Human Resource Management, to retain talented personnel within the company for the long term. It promotes learning, emphasizing practical experience for employees through new employee orientation and annual training programs, such as training related to assisted fertilization by reproductive technology, training on the future of IVF, and various specialized treatments related to infertility. In the future, the Group also plans to implement an in-house training project for medical technologists. The Group will recruit medical technologists from various universities, provide internship programs, establish practical training rooms, and offer scholarships to enhance opportunities for recruiting essential personnel and effectively managing human resources.

Production Policy (Overall)

None

Production Capacity (Overall)

ItemUnitUnit (if Other)UsedCapacity
-OthersNone00

Domestic/Overseas Purchase Proportion (Overall)

Raw MaterialSource CountryValue
-Thailand0

Projects Under Construction

Has Projects Under Construction (Y/N)

No

Debentures & Bills of Exchange

Has Debentures (Y/N)

No

Convertible Securities

Has Convertible Securities (Y/N)

No

Contents